tirzepatide 2.5 injection Zepbound mg/0.5 mL — Mountainside Medical Tirzepatide Delivers in SURMOUNT-2 -

Patients with high cardiovascular risk may benefit most from weight loss interventions, but they also require optimisation of all modifiable risk factors, including cholesterol management with statins where indicated

Weight management In SURMOUNT-1, produced up to ~22.5% mean body-weight loss at 72 weeks

Now that GLP-1/GIP products have hit the market, several studies have been conducted testing their efficacy

Many people who experience intense gastrointestinal discomfort early on have often skipped or accelerated through the titration phase

This shift prioritizes short-term financial gains over long-term investments in new research and development (R&D), often at the expense of public health

Our team at TrimBody M.D talks about this issue often during the initial treatment stages